XBiotech Inc. (NASDAQ:XBIT – Get Free Report)’s stock price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $7.19 and traded as high as $9.19. XBiotech shares last traded at $8.11, with a volume of 81,922 shares.
Analyst Ratings Changes
Separately, StockNews.com began coverage on XBiotech in a research note on Thursday, February 15th. They issued a “sell” rating on the stock.
Read Our Latest Research Report on XBiotech
XBiotech Trading Down 9.5 %
XBiotech (NASDAQ:XBIT – Get Free Report) last announced its earnings results on Friday, March 15th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter.
Institutional Trading of XBiotech
A number of institutional investors have recently made changes to their positions in XBIT. Swiss National Bank boosted its position in shares of XBiotech by 8.8% in the 1st quarter. Swiss National Bank now owns 46,800 shares of the biopharmaceutical company’s stock worth $404,000 after purchasing an additional 3,800 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of XBiotech by 72.8% in the 1st quarter. JPMorgan Chase & Co. now owns 15,093 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 6,360 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of XBiotech by 32.0% in the 1st quarter. Bank of New York Mellon Corp now owns 78,874 shares of the biopharmaceutical company’s stock worth $681,000 after purchasing an additional 19,140 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of XBiotech by 50.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 153,918 shares of the biopharmaceutical company’s stock worth $1,330,000 after purchasing an additional 51,872 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in XBiotech by 15.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 44,693 shares of the biopharmaceutical company’s stock worth $387,000 after acquiring an additional 6,085 shares during the period. Institutional investors and hedge funds own 55.70% of the company’s stock.
XBiotech Company Profile
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Featured Articles
- Five stocks we like better than XBiotech
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- United Airlines Soars on Earnings Beat
- What is a Special Dividend?
- J.B. Hunt Hits the Skids: Lower Prices to Come
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.